Project Grant R21AI183161
- This Project Grant award of $802,499, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855), aims to characterize the genetic factors involved in tuberculosis (TB) susceptibility and their interaction with the immune system. The key objectives are to: 1) generate population-level genetic data on 5,000 case-control samples from diverse South African populations to identify genetic markers associated...
- This $194,940 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) with a start date of August 12, 2025 and an ultimate completion date of July 31, 2030. The primary goal of this research project is to discover the global human genetic regulators, including genes and genetic variants, that control macrophage antimicrobial responses to Mycobacterium tuberculosis (MTB) infection....
- This $743,651 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to validate the use of plasma cell-free RNA (cfRNA) as a biomarker for the diagnosis of tuberculosis (TB) and monitoring of treatment. The grant will support the validation of cfRNA signatures in a large patient cohort of 1,378 adults across five countries, and the comparison of cfRNA diagnostic accuracy against...
- This five-year, $813,838 project grant from the National Institute of Allergy and Infectious Diseases will fund research into the genetic and hormonal mechanisms underlying sex differences in tuberculosis (TB) and TB-HIV coinfection. The Johns Hopkins University will investigate how X chromosome complement and sex steroid hormones impact TB pathogenesis using cellular models, animal studies, and human samples. Researchers will utilize a novel four core genotype mouse model to differentiate the...
- This federal Project Grant award of $743,817 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to delineate T cell receptor (TCR) families associated with protection from progression to pulmonary tuberculosis (TB) disease. The research will use advanced imaging techniques like fluorodeoxyglucose positron emission tomography and computed tomography (FDG PET-CT) to identify TB-exposed household...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), through the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $785,511 to the University of Chicago to characterize individual and population-level variability in immune responses to Mycobacterium tuberculosis (TB) and influenza virus infections. The research will leverage induced pluripotent stem cell-derived macrophages to study the genetic and epigenetic factors...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $813,450 to Case Western Reserve University to conduct research evaluating human T cells specific for Mycobacterium tuberculosis (MTB) antigens that are processed and presented by infected macrophages. The objective is to gain insight into which MTB antigens are presented and the composition and kinetics of the T cell repertoire targeting these...
- This $209,408 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, supports a research project to characterize the role of unconventional T cell subsets in the immune response to Mycobacterium tuberculosis (MTB) infection using a non-human primate model. The goal is to gain a better understanding of these niche T cell populations in the lung granulomas during the early stages of MTB...
- This Project Grant award of $104,262, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to explore the relationship between genetic variants, transcriptional responses, and tuberculosis (TB) infection outcomes in macrophages derived from genetically diverse mice. The project aims to understand the basis for variability in TB infection outcomes, which may help identify ways to...
- This $227,096 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research by the University of California, Berkeley to investigate nutrient acquisition strategies utilized by the tuberculosis pathogen Mycobacterium tuberculosis (MTB) during infection of human macrophages. The researchers have developed a novel genetic screening technique called Random Barcode Transposon Site Sequencing (RB-TnSeq) to...
INTEGRATING SINGLE-CELL OMICS AND ANCESTRY-ADJUSTED EQTL MAPPING TO CHARACTERIZE TUBERCULOSIS IMMUNE RESPONSE - TUBERCULOSIS (TB) REMAINS THE LEADING INFECTIOUS CAUSE OF DEATH WORLDWIDE. A QUARTER OF THE HUMAN POPULATION IS EXPOSED TO TB OF WHICH 5-15% WILL PROGRESS TO ACTIVE DISEASE. DESPITE ITS EXTREME PREVALENCE, PREDICTION OF DISEASE PROGRESSION IS POOR. TO ADDRESS THIS, OUR PROPOSAL INTEGRATES WHOLE GENOME SEQUENCING AND SINGLE-CELL RNA SEQUENCING (SCRNA-SEQ) ON THE ENTIRE REPERTOIRE PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) AT THREE CRUCIAL TB DISEASE STATES: LATENT TB INFECTION, RECENT MTB INFECTION, AND POST-TB TREATMENT COMPLETION. WE WILL BE THE FIRST TO LEVERAGE THIS UNIQUE STUDY DESIGN ACROSS TB STATES, FOR EXPRESSION QUANTITATIVE TRAIT LOCI (EQTL) MAPPING. OUR STUDY POPULATION IN SOUTH AFRICA RESIDES IN A TB-ENDEMIC AREA WHERE WE HAVE OVER A DECADE OF ESTABLISHED RESEARCH INFRASTRUCTURE, ENABLING US TO EFFICIENTLY CAPTURE THESE CRITICAL TB PHENOTYPES AT A RELATIVELY LOW COST. PREVIOUS TB EQTL MAPPING STUDIES HAVE BEEN LIMITED BY INADEQUATE PHENOTYPING (E.G., SAMPLES FROM TB CASES MONTHS- YEARS AFTER CLEARING INFECTION), BULK RNA-SEQ (AGGREGATING CELL-TYPE SPECIFIC EFFECTS), OR SCRNASEQ ON ONE CELL TYPE. WE ARE GENERATING CITE-SEQ PROFILES FROM PBMCS, A CUTTING-EDGE TECHNOLOGY THAT ENABLES SIMULTANEOUS PROFILING OF GENE EXPRESSION AND CELL SURFACE PROTEIN COMPOSITION AT THE SINGLE-CELL LEVEL [FUNDED BY CZI, CO-PI SULIMAN]. THIS APPROACH ALLOWS US TO CAPTURE THE FINE-SCALE HETEROGENEITY OF IMMUNE CELL STATES. TO IDENTIFY THE GENETIC VARIANTS THAT REGULATE THESE IDENTIFIED CELLULAR AND TRANSCRIPTOMIC CHANGES, WE PROPOSE TO GENERATE WHOLE GENOME SEQUENCING DATA PAIRED WITH THE TRANSCRIPTOMIC DATA FOR EQTL FINE-MAPPING. SOUTH AFRICAN POPULATIONS EXHIBITS HIGH LEVELS OF GENETIC HETEROZYGOSITY AND ARE MULTIWAY ADMIXED, AMPLIFYING STATISTICAL POWER FOR DISCOVERING EQTL VARIANTS. TO CHARACTERIZE THE UNIQUE GENETIC DIVERSITY OF OUR POPULATION WE HAVE OPTIMIZED STATE-OF-THE-ART ANCESTRY ESTIMATION METHODS. OUTCOMES OF THIS GRANT INCLUDE MULTIOMIC DATA FROM 225 INDIVIDUALS ACROSS THREE TB STATES AND EQTL IDENTIFICATION OF ANCESTRY- AND CELL-SPECIFIC VARIANTS WHICH AFFECT GENE EXPRESSION IN EARLY TB INFECTION.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $43.2k | 8/25/25 | ||
| Not listed | $92.6k | 8/21/25 | ||
| Not listed | $27.2k | 9/11/24 | ||
| Not listed | $245.0k | 7/26/24 | ||
| Not listed | $245.0k | 7/26/24 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
A241745S002S | Stellenbosch University | Project Grant R21AI183161 | $57.8k | 12/10/24 |